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1 Equal contributions.GPR35 is an orphan G protein-coupled receptor that is not well-characterized. Here we employ
dynamic mass redistribution (DMR) assays to discover new GPR35 agonists. DMR assays identiﬁed
tyrphostin analogs as GPR35 agonists, which were conﬁrmed with receptor internalization, Tango
b-arrestin translocation, and extracellular-signal-regulated kinase phosphorylation assays. These
agonists provide pharmacological tools to study the biology and function of GPR35.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
GPR35 was ﬁrst identiﬁed to be a class A orphan G protein-
coupled receptor (GPCR) that contains 309 amino acids [1].
GPR35b, a splicing variant that contains an N-terminal extension
of 31 amino acids, was later discovered in gastric cancer cells in
2004, and shown to be capable of transforming NIH-3T3 cells
[2]. GPR35 has been found to be expressed in various tissues
including stomach [2], gastrointestinal tissues [3], and mast cells,
basophils and eosinophils [4]. Upregulation of GPR35 has also
been identiﬁed in human mast cells upon challenge with IgE anti-
bodies [4], in human macrophages after exposure to benzo(a)pyr-
ene [5], in failing heart cells [6], and in gastric cancer cells [2]. To
date, both kynurenic acid and 2-acyl lysophosphatidic acids have
been postulated to be natural agonists for GPR35 [7,8]. Both li-
gands elicited cellular responses via GPR35 in engineered cells
expressing GPR35. However, it remains controversial whether
both agonists are true endogenous agonists, and it is largely un-
known about the biological functions of GPR35 [9]. Thus, identiﬁ-
cation of new classes of ligands would be beneﬁcial to elucidate
the biology and pharmacology of GPR35. Here, we applied a path-
way-unbiased, but pathway-sensitive technology, dynamic masschemical Societies. Published by E
n; GPCR, G protein-coupled
xtracellular-signal-regulatedredistribution (DMR) assay [10], to discover new GPR35 ligands.
The DMR assay is enabled by label-free resonant waveguide grat-
ing (RWG) biosensor [11], and has attracted much interest in the
molecular delineation of receptor biology and ligand pharmacol-
ogy [12–14]. DMR agonism screening in HT-29, a human colon
cancer cell line that endogenously expresses GPR35, led to identi-
ﬁcation of tyrphostin analogs including entacapone as GPR35
agonists.2. Materials and methods
2.1. Materials and cells
Tyrphostins and entacapone were obtained from Sigma Chemi-
cal Co. (St. Louis, MO, USA). Zaprinast and BioMol 80 kinase inhib-
itor library was purchased from Enzo Life Sciences (Plymouth
Meeting, PA). The InhibitorSelect™ 96-well protein kinase inhibi-
tor library I (Cat. No. 539744) and II (Cat. No. 539745) were pur-
chased from EMD Chemicals (Gibbstown, NJ, USA). All inhibitors
were stocked in dimethyl sulfoxide (DMSO) at 10 mM, and were
diluted directly in the assay buffer (1 Hanks’ balanced salt buffer,
20 mM Hepes, pH 7.1; HBSS) to the indicated concentrations. Epic
384-well biosensor microplates were obtained from Corning Inc.
(Corning, NY, USA). Mouse monoclonal anti-phosphorylated extra-
cellular-signal-regulated kinase 1/2 (anti-pERK1/2) (Cat. #M9682)
and mouse monoclonal anti-ERK1/2 (#M7431) were obtained from
Sigma. Goat anti-GPR35 antibody (#T14, cytoplasmic) was pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).lsevier B.V. All rights reserved.
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Invitrogen (Carlsbad, CA, USA).
Human colorectal adenocarcinoma HT-29 was obtained from
American Type Cell Culture (Manassas, VA). The cells were cul-
tured in McCoy’s 5a Medium Modiﬁed supplemented with 10% fe-
tal bovine serum, 4.5 g/l glucose, 2 mM glutamine, and antibiotics
at 37 C under air/5% CO2.
Tango™ GPR35-bla U2OS cells were obtained from Invitrogen.
Tango™ GPR35-bla U2OS cells contain the human GPR35 linked
to a TEV protease site and a Gal4-VP16 transcription factor stably
integrated into the Tango™ GPR35-bla U2OS parental cell line. This
parental cell line stably expresses a b-arrestin/TEV protease fusion
protein and the b-lactamase reporter gene under the control of a
UAS response element. The cells were cultured according to the
protocols recommended by the supplier. Brieﬂy, the cells were
passed using McCoy’s 5A medium (Invitrogen 16600-082) supple-
mented with 10% dialyzed fetal bovine serum, 0.1 lM NEAA,
25 lMHepes (pH 7.3), 1 mM sodium pyruvate, 100 U/ml penicillin,
100 lg/ml streptomycin, 200 lg/ml zeocin, 50 lg/ml hygromycin,
and 100 lg/ml geneticin in a humidiﬁed 37 C/5% CO2 incubator.
2.2. DMR assays using Epic system
All DMR assays were performed using Epic system (Corning
Inc.). Epic is a wavelength interrogation reader system tailored
for RWG biosensor in microtiter plates. This system consists of a
temperature-control unit (26 C), an optical detection unit, and
an on-board liquid handling unit with robotics. The detection unit
is centered on integrated ﬁber optics, and enables kinetic measures
of cellular responses with a time interval of 15 s. Cells were di-
rectly seeded in Epic plates and cultured overnight to form con-
ﬂuent monolayer in the cell culture medium. After being washed
twice, the cells were maintained with HBSS and further incubated
inside the system for 1 h. For agonism screen, a 2-min baseline was
then established. Immediately after the compound addition using
the onboard liquid handler, the cellular responses were recorded.
For desensitization assays, cells were initially treated with com-
pounds for 1 h, followed by stimulation with zaprinast at a ﬁxed
dose. The cellular responses were recorded throughout the assays.
All EC50 or IC50 described in the main text were calculated based on
the amplitudes of DMR signals at 8 min post-agonist stimulation.
Since all GPR35 agonists led to a sustained positive-DMR (P-
DMR) signal, the amplitudes at 50 min post-stimulation were also
used to determine kinetics dependent potency and efﬁcacy of all li-
gands (see Table 1).Table 1
Compound name, and its efﬁcacy relative to the maximal response induced by zaprinast,
which were obtained using DMR assays. EC50 obtained using Tango assays were also inclu
Compound % zaprinast at EC100 EC50 (lM)
P-DMR (8 min) P-DMR (50 min) P-DMR (8
Zaprinast 100 100 0.16 ± 0.02
Tyrphostin-1 Inactive Inactive Inactive
Tyrphostin-9 11 ± 3 63 ± 1 n.a.
Tyrphostin-23 94 ± 4 109 ± 5 3.0 ± 0.3
Tyrphostin-25 107 ± 9 102 ± 8 0.94 ± 0.07
Tyrphostin-46 74 ± 6 83 ± 5 4.6 ± 0.2
Tyrphostin-47 80 ± 5 101 ± 6 3.9 ± 0.2
Tyrphostin-51 98 ± 4 99 ± 9 0.19 ± 0.02
AG-126 54 ± 13 97 ± 15 11.9 ± 0.4
AG-490 Inactive Inactive Inactive
AG-494 28 ± 1 95 ± 3 n.a.
AG-825 55 ± 8 65 ± 13 15.2 ± 3.1
AG-1024 40 ± 10 117 ± 11 n.a.
AG-1288 78 ± 2 80 ± 7 0.44 ± 0.04
Entacapone 97 ± 3 140 ± 5 6.3 ± 0.72.3. Receptor internalization assays
HT29 cells were plated on an 8-well chamber slide with a
seeding density of 10 000 cells/well and incubated at 37 C for
24 h. Next day, cells were stimulated with a compound or equal
amount of DMSO at 37 C for 1 h. Afterwards, cells were ﬁxed
with 4% formaldehyde in 1 PBS for 15 min, followed by block-
ing and permeabilization in a buffer containing 4% goat serum,
0.1% bovine serum albumin (BSA), 0.1% Triton X100 in 1 PBS
for 2 h. After 5 min wash with PBS, ﬁxed cells were incubated
with the anti-GPR35 (1:500) in 3% BSA/PBS buffer for 24 h, fol-
lowed by incubation with secondary antibody Alexa Fluor 594
donkey anti-goat IgG (H + L) (1:500) in 3% BSA/PBS for 1 h at
room temperature. Cells were ﬁnally washed once with PBS
and sealed with 1.5 mm thick glass cover-slip. Dried slides were
stored at 4 C until imaging. Confocal imaging was performed
with Zeiss confocal microscope Axiovert 40. Confocal images
were analyzed using MacBiophotonics Image J software (http://
www.macbiophotonics.ca/downloads.htm).
2.4. ERK MAPK assays
The p44/42 MAP kinases were examined using Western blot-
ting. Whole cell lysates were collected after the cells were treated
with a compound or DMSO for 1 h. Equivalent gel loading was con-
ﬁrmed by probing with anti-actin body. The total ERK1/2 and phos-
phorylated ERK1/2 were blotted using respective antibodies.
2.5. Tango™ b-arrestin assays
The Tango™ GPR35 b-arrestin assay takes advantage of GPR35
agonist-induced recruitment of protease tagged beta-arrestin
molecules to GPR35 that has been modiﬁed at the C-terminus
to include a transcription factor linked by a protease cleavage
site. As a result of arrestin recruitment, the protease cleaves the
transcription factor from the receptor, which then translocates
to the nucleus and activates the expression of beta-lactamase.
The assay protocol recommended by the supplier was used.
Brieﬂy, 10 000 cells/well were seeded in 384-well, black-wall,
clear bottom assay plates with low ﬂuorescence background
(Corning), and cultured in DMEM (Invitrogen, 10569-010) supple-
mented with 10% dialyzed fetal bovine serum, 0.1 lM NEAA,
25 lM Hepes (pH 7.3), 100 U/ml penicillin, and 100 lg/ml strep-
tomycin. After overnight culture, the cells were stimulated with
ligands for 5 h in a humidiﬁed 37 C/5% CO2, and then loadedEC50 at 8 min or 50 min post-stimulation, apparent IC50 to desensitize the cells, all of
ded.
EC50 (lM) IC50 (lM) EC50 (lM) (Tango)
min) P-DMR (50 min)
0.05 ± 0.01 0.32 ± 0.04 6.2 ± 0.9
Inactive Inactive Inactive
1.0 ± 0.2 Inactive Inactive
2.0 ± 0.2 4.0 ± 0.5 >60
0.70 ± 0.05 0.94 ± 0.07 5.3 ± 1.1
1.9 ± 0.2 5.4 ± 0.6 >60
2.8 ± 0.4 2.7 ± 0.3 19.2 ± 3.1
0.11 ± 0.03 0.21 ± 0.05 7.7 ± 0.9
10.2 ± 0.9 27.1 ± 3.0 Inactive
Inactive Inactive Inactive
12.5 ± 2.1 35 ± 7 Inactive
9.5 ± 2.3 16.1 ± 4.1 Inactive
2.4 ± 1.2 >32 Inactive
0.21 ± 0.04 0.70 ± 0.06 25.3 ± 4.7
31.7 ± 4.1 6.6 ± 0.9 Inactive
H. Deng et al. / FEBS Letters 585 (2011) 1957–1962 1959with the cell permeable LiveBLAzer™ FRET B/G substrate. After
the 2 h incubation the coumarin:ﬂuorescein ratio was measured
using Tecan Saﬁre II microplate reader (Männedorf, Switzerland).
The FRET B/G substrate contains two ﬂuorophores, coumarin and
ﬂuorescein, in which excitation of the coumarin results in ﬂuores-
cence resonance energy transfer to the ﬂuorescein moiety and
emission of green ﬂuorescent light. In the absence of beta-lacta-
mase expression (i.e., no GPR35 activation), cells generate green
ﬂuorescence. In the presence of beta-lactamase expression upon
receptor activation, the substrate is cleaved and the cells generate
blue ﬂuorescence. The coumarin:ﬂuorescein ratio was used as a
normalized reporter response.
3. Results
3.1. Characteristics of known GPR35 agonists in HT29
To determine the presence of functional GPR35 in HT29, we
ﬁrst examined the DMR responses induced by three known
GPR35 agonists including zaprinast [15], pamoic acid [16], and
kynurenic acid [7]. Results showed that all three ligands gave rise
to a dose-dependent and saturable response (Fig. 1a); and the
EC50 values were found to be 2.1 ± 0.2 nM (n = 4), 0.16 ± 0.02 lM
(n = 4), and 152 ± 17 lM (n = 4) for pamoic acid, zaprinast, and
kynurenic acid, respectively (Fig. 1b). All three agonists also
dose-dependently desensitized the cells to the repeated stimula-
tion with 1 lM zaprinast, leading to an apparent IC50 of-50
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Fig. 1. Characterization of three known GPR35 agonists including zaprinast, pamoic acid
DMR amplitudes of three agonists as a function of their doses. (c) The DMR amplitudes
stimulated with distinct agonists at different doses for 1 h. The amplitudes at 8 min pos
image of unstimulated HT29 cells. (e) The confocal image of HT29 cells 1 h after stim
permeabilized and stained with anti-GPR35, followed staining with the ﬂuorescent seco3.9 ± 0.2 nM (n = 4), 1.22 ± 0.10 lM (n = 4), and 234 ± 25 lM
(n = 4) for pamoic acid, zaprinast, and kynurenic acid, respectively
(Fig. 1c). Immunostaining with anti-GPR35 showed that GPR35
was presented and located primarily at the cell plasma mem-
brane in unstimulated HT29 cells (Fig. 1d), and got partially inter-
nalized by 10 lM pamoic acid (Fig. 1e). Together, these results
suggest that GPR35 in HT29 is functional, and all three ligands
are indeed agonists for GPR35.
3.2. DMR agonism screen
Next, we screened three kinase libraries that include a total of
240 known kinase inhibitors, using DMR agonism assay. Each
inhibitor was assayed with four replicates. Zaprinast was included
as a positive control. Hits were selected based on their maximal
responses within 15 min post-stimulation that are greater than
30% of the zaprinast response. Twenty-ﬁve hits were identiﬁed
(Fig. 2). Follow-up structure activity analysis showed that 11
out of the 25 hits are tyrphostins, including AG-112, AG-1024,
tyrphostin-51, tyrphostin-25, tyrphostin-47, AG-370, AG-1288,
tyrphostin-23, AG-126, tyrphostin-46, and AG-825 (Fig. 3). Fur-
ther, AG-494, AG-879, tyrphostin-9, and quercetin also led to
noticeable DMR. The other ﬁve tyrphostins including AG-490,
AG-1478, AG-1295, AG-1296, and tyrphostin-1 in the libraries
did not trigger any noticeable DMR. Quercetin was recently iden-
tiﬁed to be a GPR35 partial agonist [17]. These results suggest
that tyrphostins are possible GPR35 agonists.-10 -9 -8 -7 -6 -5 -4 -3
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Fig. 2. The DMR responses as a function of compounds. Each compound was
assayed at four replicates. The DMR amplitudes of all compounds at 8 min post-
simulation were plotted.
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The three kinase libraries consist of 19 tyrphostin analogs, 14 of
which led to detectable DMR when being screened at 10 lM. Thus,
we were focused on characterization of tyrphostins. We ﬁrst exam-
ined 13 tyrphostins for their dose-dependent responses in HT29
cells using DMR assays. Results showed that except for tyrphostin-
1 and AG-490, all tyrphostins tested gave rise to dose-dependent re-
sponses (Fig. 4a). Further, these tyrphostins differ greatly in potency
and efﬁcacy (Table 1). Tyrphostin-51, tyrphostin-23 and tyrphostin-
25 acted as full agonists, while others were partial agonists.
Searching the DrugBank database (http://www.drugbank.ca/)
identiﬁed entacapone that is a tyrphostin analogy drug (Fig. 3).
Entacapone is a selective, reversible catechol-O-methyl transferaseO
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Thus, we characterized entacapone using DMR assays. Results
showed that entacapone led to a dose-dependent DMR with an
EC50 of 6.3 ± 0.7 lM (n = 4), whose DMR characteristics is similar
to other GPR35 agonists including zaprinast and tyrphostin-51
(Fig. 4b). Similar to tyrphostin-51, entacapone also dose-depen-
dently desensitized the cells responding to the repeated stimula-
tion with 1 lM zaprinast, leading to an apparent IC50 of
31.7 ± 4.1 lM (n = 4) (Fig. 4c). These results suggest that entaca-
pone may also be a GPR35 agonist.
3.4. GPR35 internalization, ERK phosphorylation and arrestin
translocation induced by tyrphostins
Since tyrphostin-51 is the most potent ligand among tyrphos-
tins in DMR assays, we examined its ability to cause receptor inter-
nalization. Results showed that stimulation of HT29 with 10 lM
tyrphostin-51 led to signiﬁcant internalization of GPR35 (Fig. 5a).
SinceERKphosphorylation is a hallmarkof the activation and sig-
nalingofmanyGPCRs includingGPR35 [16],weexamined theability
of both tyrphostin-51 and entacapone to result in ERK phosphoryla-
tion. Results showed that stimulation of HT-29 cells with both ago-
nists led to robust phosphorylation of ERK (Fig. 5b). As a control, the
knownGPR35 agonist zaprinast also led to robust ERK phosphoryla-
tion, while tyrphostin-1 was inactive as expected (Fig. 5b).
Finally, we examined the ability of tyrphostins to cause arrestin
translocation using the Tango™ GPR35 arrestin assays. Results
showed that zaprinast led to a dose dependent response in Tango™
GPR35-bla U2OS cells with an EC50 of 6.2 ± 0.9 lM (n = 4) (Fig. 6a;
Table 1). Similarly, tyrphostin-51 also led to a comparable response,
leading to an EC50 of 7.7 ± 0.9 lM (n = 4) (Fig. 6b), suggesting that
similar to zaprinast tyrphostin-51 acted as a full agonist for GPR35CN
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tins including tyrphostin-23, tyrphostin-25, tyrphostin-46, tyrpho-
stin-47 and AG-1288 acted as partial agonists (Fig. 6), while other
tyrphostins tested were inactive. It is worthy noting that the Tango
arrestin assay generally led to a right shift in potency. Nonetheless,
these results suggest that tyrphostins including entacapone are
GPR35 agonists.4. Discussion
GPR35 is a poorly-characterized orphan GPCR with a few known
agonists. To identify GPR35 ligands, we ﬁrst showed that GPR35 is
present and located primarily at the cell surface of native HT29 cells
(Fig. 1d). DMR assays further showed that endogenous GPR35 in
HT29 is functional,whoseactivationby threeknownGPR35agonists
1962 H. Deng et al. / FEBS Letters 585 (2011) 1957–1962leads to robust DMR signals (Fig. 1a and b). Screening three kinase
inhibitor libraries using DMR agonism assay led to identiﬁcation of
14 tyrphostin analogs that acted as GPR35 agonists. Among all tyr-
phostins examined, tyrphostin-51 was found to be the most potent
ligand with an EC50 of 190 nM (Fig. 4a), which is comparable to the
potency of zaprinast. Tyrpostin-51 resulted in signiﬁcant internali-
zation of GPR35, the degree of which is comparable to that induced
by pamoic acid (Fig. 5a). Further, tyrophstin-51 also led to robust
ERK phosphorylation (Fig. 5b) and b-arrestin translocation
(Fig. 6b). Tyrphostins were originally designed and developed for
inhibiting tyrosine kinases [19]. Like all kinase inhibitors tyrphos-
tins often interact with multiple targets. Thus, the identiﬁcation of
tyrphostins as potent GPR35 agonists adds new target class to these
kinase inhibitors.
One of the most notable ﬁndings of this study is that entacapone
was identiﬁed to be a GPR35 agonist with a moderate potency.
Chemical similarity searching of the Drug Bank database allowed
us to identify entacapone as a tyrphostin analog drug. Follow-up
DMR and receptor signaling assays showed that (1) entacapone re-
sulted in a DMR similar to other GPR35 agonists; (2) entacapone
caused cells desensitized upon the repeated stimulationwith zapri-
nast; and (3) entacapone behaved similarly to tyrphostin-51 in
receptor signaling assays. Entacapone was apparently inactive in
the Tango™ arrestin gene reporter assays within the concentration
range examined. However, due to the right shift in potency in the
arrestin assays, we cannot rule out the possibility of entacapone to
be a weak agonist in causing arrestin translocation. Entacapone is
a nitrocatechol drug that is used in the treatment of Parkinson’s dis-
ease in conjunction with dopaminergic agents. The primarymecha-
nism of action is believed to be that entacapone acts as a CMOT
inhibitor, thus preventing COMT from metabolizing L-DOPA into 3-
methoxy-4-hydroxy-L-phenylalanine in the periphery, which does
not easily cross the blood–brain barrier. The moderate potency of
entacapone observed here raises an intriguing point whether its
GPR35 agonism activity is relevant to its clinical features.
In conclusion, the ligands identiﬁed here provide new pharma-
cological tools to characterize the biology and pharmacology of
GPR35. The present study also highlights the power of label-free
DMR assays to discover new ligands for poorly characterized
receptors, including GPR35.
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